Compare ARK Genomic Revolution ETF (ARKG) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KKR & Co Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while KKR & Co Inc trades at $96.68 (market cap $87.04B). The key difference: KKR & Co Inc pays a 0.77% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, KKR & Co Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | KKR | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $152.16 |
52-Week Low | $23.09 | $83.88 |
Market Cap | — | $87.04B |
Enterprise Value | — | $12.56B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
KKR trades at $96.94, up 0.7% today, with a bullish technical outlook supported by moving averages and near-term resistance at $97. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic acquisitions like the $4.2 billion EDF power solutions deal and a $1.3 billion renewable energy platform in South Korea. Strong analyst sentiment includes 24 buy ratings and a consensus price target of $127.71, indicating significant upside potential.
The outlook for KKR is positive, driven by robust monetization activity, strategic growth initiatives, and a favorable analyst consensus. Key risks include volatile cash flows from operations, high leverage with long-term debt of $49.91 billion, and dependence on private market conditions. Investors should weigh the growth opportunities against these financial and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
